In the context of diagnosis and follow-up of urothelial diseases, particularly bladder cancer, two diagnostic tools play a central role: cystoscopy and urinary cytology. Although both techniques are widely used, they have distinct characteristics, advantages and limitations. This article proposes a comparative analysis of the two approaches, evaluating their respective clinical indications and offering evidence-based recommendations.

Cystoscopy is an endoscopic examination that allows direct inspection of the bladder mucosa by means of a flexible or rigid instrument inserted into the urethra.

Strengths
- Real-time visualization: allows direct identification of suspicious lesions, nodularities, or mucosal abnormalities.
- Possibility of biopsy or resection: allows therapeutic interventions (e.g. transurethral resection).
- High sensitivity for visible tumors, including low-grade papillary tumors.

Limitations
- Invasive examination, with possible discomfort, risk of infection or bleeding.
- Does not always detect flat lesions such as carcinoma in situ (CIS).
- Higher cost and resources than cytology.

Urinary cytology consists of microscopic analysis of exfoliated cells in urine, looking for morphologic changes indicative of malignancy.

Strengths
- Non-invasive, easily repeatable test.
- High specificity (>90%), particularly useful for identifying carcinoma in situ and high-grade tumors.
- Good adjunct in postoperative follow-ups.

Limitations
- Low sensitivity for low-grade tumors (20-50%).
- Results can be influenced by technical and subjective factors, such as sample quality and cytopathologist's experience.
- Often requires histologic confirmation.

- Initial diagnosis of suspected hematuria: cystoscopy is the main investigation; cytology may be useful in selected cases.
- Follow-up after TURB (transurethral resection of bladder tumor): both tests are recommended, with cytology particularly useful for detecting high-grade recurrence or CIS.
- Suspected carcinoma in situ: combination of urinary cytology and cystoscopy with possible random biopsy is recommended.
- High-risk patients (e.g., history of bladder cancer): both tests are used synergistically, according to EAU/AUA guidelines.

- Integrated approach: no test is completely self-sufficient. The combination of cystoscopy and cytology provides the highest diagnostic accuracy.
- Personalization of the diagnostic pathway: the choice between the two tests (or their combined use) should be guided by factors such as the patient's clinical risk, suspected tumor type, oncologic history, and individual tolerability.

Cystoscopy and urinary cytology represent two complementary tools in the diagnosis and monitoring of bladder neoplasms. While cystoscopy remains the standard for visual identification and immediate management of lesions, cytology plays an essential role in detecting high-grade tumors that are not visible. An integrated, balanced and individualized approach is the most effective strategy to optimize diagnostic accuracy and improve clinical outcomes for patients.